Subcutaneous CLN-978 for treatment‑refractory rheumatoid arthritis
Official title: A Phase I, Open-Label Study of CLN-978 in Patients With Treatment-Refractory Rheumatoid Arthritis (RA)
Run by Cullinan Therapeutics Inc. · NCT06994143 · Data updated 2026-11-12
This Phase I trial tests a subcutaneously given drug called CLN-978 that redirects T cells to CD19 to try to help people with treatment‑refractory, B‑cell–driven rheumatoid arthritis.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 37 (estimated) |
| Sponsor | Cullinan Therapeutics Inc. Industry-sponsored |
| Drugs / interventions | blinatumomab, obinutuzumab, rituximab, ocrelizumab, ofatumumab, CAR-T, chimeric antigen receptor, Cyclophosphamide, prednisone |
| Locations | 4 sites (Erlangen and 3 other locations) |
| Status | Recruiting |
| Started | May 19, 2025 |
| Main results expected | December 30, 2027 |
| Study ends | December 30, 2028 |
| Registry record updated | October 20, 2026 |
| Trial ID | NCT06994143 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with RA meeting 2010 ACR/EULAR criteria who have active disease (DAS28‑ESR ≥3.2), evidence of B‑cell–driven disease (RF/AMPA positivity or synovial B‑cell infiltration), prior inadequate response to at least two targeted therapies, and meeting required lab thresholds (ALC ≥0.5 x10^9/L, CD19+ ≥25 cells/µL, ANC ≥1.0 x10^9/L, Hgb ≥8 g/dL, platelets ≥75 x10^9/L) are the intended participants.
✕Probably not a fit
Patients whose disease is not B‑cell driven, who have very low peripheral B cells (<25 cells/µL), who respond well to standard treatments, or who do not meet the laboratory safety criteria are unlikely to benefit from this trial.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is an open‑label Phase I trial of CLN-978, a CD19‑directed T cell engager given subcutaneously to adults with active, treatment‑refractory rheumatoid arthritis. Participants must have evidence of B‑cell‑driven disease (seropositivity for RF/AMPA or synovial B‑cell infiltration), a DAS28‑ESR ≥3.2, and prior inadequate response to at least two targeted therapies. The trial enrolls patients who meet specific laboratory thresholds for lymphocytes, peripheral CD19+ B cells, neutrophils, hemoglobin, and platelets to support safety monitoring. The primary focus in this early‑phase trial is safety and tolerability with initial dosing and clinical observation in a small, selected population.
Why it matters
Potential benefit: If successful, CLN-978 could reduce B‑cell–mediated joint inflammation and improve symptoms in people with refractory RA.
How similar studies have gone: B‑cell‑depleting therapies such as anti‑CD20 agents (e.g., rituximab) have proven benefit in RA, but CD19‑directed T cell engagers like CLN‑978 are a novel approach with limited prior clinical data in autoimmune disease.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Documented diagnosis of RA which fulfills the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) Classification Criteria ≥12 weeks prior to screening. * Evidence of B-cell-driven disease at Screening or previous medical documentation, defined as either (i) seropositivity for RF and/or any AMPA and/or (ii) a synovial biopsy showing B-cell infiltration * Active RA disease, as demonstrated by a DAS28 - ESR ≥3.2 and at least one swollen joint at screening. * Inadequate response to at least 2 targeted treatments with different mechanisms. These can include tsDMARD and/or bDMARD, after failing conventional synthetic DMARD (unless contraindicated). * Local laboratory assessments must meet the following criteria: * Absolute lymphocyte count (ALC) ≥0.5 x 10\^9/L * Peripheral CD19+ B cell count ≥25 cells/μL * Absolute neutrophil count (ANC) ≥1.0 x 10\^9/L * Hemoglobin (Hgb) ≥8 g/dL * Platelet count ≥75 x 10\^9/L * Estimated glomerular filtration rate (eGFR) (based on the Chronic Kidney Disease Epidemiology Collaboration \[CKD-EPI\] formula) ≥30 mL/min/1.73m\^2 * Total bilirubin ≤1.5 × ULN, except patients with confirmed Gilbert's Syndrome * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 × ULN * Concurrent corticosteroids is permitted if the dose is ≤10 mg/day prednisone equivalent in the 2 weeks prior to initiation of study treatment. Hydroxychloroquine ≤400 mg/d or chloroquine ≤ 250 mg/d is allowed. Exclusion Criteria: * Active inflammatory disease other than RA within 12 months prior to screening or during screening that may interfere with the study assessments. Thyroiditis or secondary Sjogren's syndrome is allowed. * Clinical evidence of any other significant unstable or uncontrolled acute or chronic disease not due to RA which, in the opinion of the Investigator could put the patient at undue risk or confound study results. * Prior treatment with the following: * Cellular therapy (e.g., chimeric antigen receptor T-cell (CAR-T) or gene therapy product directed at any target. * Receipt of an investigational therapy within 30 days or 5 drug-elimination half-lives (whichever is longer) prior to Day 1 and during the study. * Received any anti-CD19 or anti-CD20 therapy such as blinatumomab, obinutuzumab, rituximab, ocrelizumab, or ofatumumab within 3 months prior to Day 1. * Non-biologic DMARD within 14 days prior to Day 1. * Cyclophosphamide or a biologic immunomodulating therapy within 2 months of Day 1. * Live or live-attenuated vaccines within the 4 weeks prior to the Screening visit or during the Screening Period * Active or latent tuberculosis (TB) evidenced by a positive or indeterminant Interferon Gamma Release Assay (IGRA), unless the patient has documented previous completion of TB treatment and no current clinical indication of TB.
Where it's running
-
University Hospital Erlangen
Erlangen, Germany Recruiting -
University Hospital Heidelberg
Heidelberg, Germany Recruiting -
Fondazione Policlinico Universitario A Gemelli
Rome, Italy Recruiting -
Humanitas Research Hospital
Rozzano, Italy Recruiting
Study contacts
- Study coordinator: Amy Gubits, MPH
- Email: ClinOps@cullinantx.com
- Phone: +1 617 410 4650
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Heart Rate Variability and Rheumatoid Arthritis: What HRV Looks Like with RA
This study checks whether continuous HRV data from an Oura ring can reflect RA disease activity in adults with RA.
-
Discontinuing MTX or LEF in RA Patients on TNF Inhibitors
This trial tests whether stopping methotrexate or leflunomide while continuing a TNF inhibitor is not worse for disease control in adults with rheumatoid arthritis.
-
FT839 therapy for autoimmune diseases
This trial tests FT839, given alone or with rituximab, to see if it is safe and can help people with certain autoimmune diseases who have not responded to other treatments.
-
24-Hour Movement and Atherosclerotic Risk in adults with rheumatoid arthritis
This study tests how daily activity, sitting, and sleep relate to heart-related risk in adults with RA, using wearables and follow-up after a year.
-
Integrative AI profiling of chronic RA pain
This study tests whether an AI-driven multiomic and neurophysiological approach can help explain and predict persistent pain in adults with active rheumatoid arthritis.
-
Oxidative Stress and Heart Risk in People with Rheumatoid Arthritis
This study tests whether certain markers of oxidative stress in people with rheumatoid arthritis are linked to subclinical atherosclerosis and arterial stiffness, which could relate to future heart disease risk.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.